Molecular structure of Raloxifene, CAS Number: 84449-90-1
Raloxifene (CAS 84449-90-1)
See product citations (3)
Alternate Names:
Keoxifene; LY 139481
CAS Number:
84449-90-1
Molecular Weight:
473.58
Molecular Formula:
C28H27NO4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Raloxifene interacts with estrogen receptors in the cell, acting as a selective estrogen receptor modulator. It exerts its effects by binding to estrogen receptors and modulating their activity, leading to changes in gene expression and cellular processes. Raloxifene inhibits the proliferation of breast cancer cells by blocking estrogen receptor signaling pathways. Raloxifene effects on lipid metabolism, reducing levels of LDL cholesterol.
Raloxifene (CAS 84449-90-1) References
- Raloxifene to prevent postmenopausal osteoporosis. | . 1999. Drug Ther Bull. 37: 33-6. PMID: 10563056
- Raloxifene: a review of its use in postmenopausal osteoporosis. | Clemett, D. and Spencer, CM. 2000. Drugs. 60: 379-411. PMID: 10983739
- Raloxifene: risks and benefits. | Barrett-Connor, E. 2001. Ann N Y Acad Sci. 949: 295-303. PMID: 11795366
- [Raloxifene and breast: from the SERMs concept to its place in clinical practice]. | This, P. and Guyot, B. 2004. Gynecol Obstet Fertil. 32: 75-84. PMID: 14736604
- Raloxifene and its role in breast cancer prevention. | Eng-Wong, J. and Zujewski, JA. 2004. Expert Rev Anticancer Ther. 4: 523-32. PMID: 15270657
- [Raloxifene in postmenopausal women]. | Trémollières, F. and Ribot, C. 2006. Gynecol Obstet Fertil. 34: 147-53. PMID: 16483822
- Raloxifene and the prevention of breast cancer. | Bevers, TB. 2006. Expert Opin Pharmacother. 7: 2301-7. PMID: 17059385
- Raloxifene in breast cancer prevention. | Gennari, L., et al. 2008. Expert Opin Drug Saf. 7: 259-70. PMID: 18462184
- Raloxifene for older women: a review of the literature. | Hansdóttir, H. 2008. Clin Interv Aging. 3: 45-50. PMID: 18488877
- Raloxifene: a review of its use in the prevention of invasive breast cancer. | Moen, MD. and Keating, GM. 2008. Drugs. 68: 2059-83. PMID: 18778124
- Raloxifene use in clinical practice: efficacy and safety. | Goldstein, SR., et al. 2009. Menopause. 16: 413-21. PMID: 19092711
- Long-term raloxifene for postmenopausal osteoporosis. | Recker, RR., et al. 2011. Curr Med Res Opin. 27: 1755-61. PMID: 21787127
- Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. | Wang, Q., et al. 2018. Arch Womens Ment Health. 21: 31-41. PMID: 28849318
- The effects of raloxifene on endothelial function and Inflammation in Postmenopausal women: A Meta-analysis of randomized controlled trials. | Kang, F., et al. 2022. Exp Gerontol. 159: 111682. PMID: 34973344
Inhibitor of:
μ-crystallin, 17-β Estradiol, 17-β Estradiol 6, AADACL1, AMDHD1, AOX1, AOX3, AOX4, ARHGAP19, Arrestin-C, c-Erb-A α, CYP2C8, DHRS12, EEIG1, ER, ER alpha, ER beta, ERRγ, ES, Estradiol, Estriol, Gm694, GREB1, Gros1, HSDL1, IP3KB, LOC100039517, LRIF, LRP16, LRRC17, MOCA, NELL1, NFATc4, NOBOX, NPIPL3, Olfr1032, Olfr250, Olfr508, Olfr806, Olfr807, Olfr808, Olfr809, Olfr810, Olr235, Olr257, Olr403, Olr707, PINLYP, Plfr, PR, PRAT4B_Cnpy4, Sdt, SR-A, TMEM31, TRβ1, TR2, Trap1a, TSARG6, UGT2B15, UGT2B17, V1RB7, V1RB8, and ZP2.Activator of:
ABCG2, CaMKIIγ, CRISP-4, CYP26A1, EEIG1, FKBPL, GCDFP-15, GIPC, HRC, IFITM5, Lamin B2, megalin, OG1, OG2, PIG-K, pS2, SMR3A, and SRC-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Raloxifene, 1 g | sc-476458 | 1 g | $802.00 |